Jubilant Pharmova (530019) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
10 Aug, 2026Executive summary
Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved by the Board and subjected to limited review by statutory auditors.
Both standalone and consolidated results were prepared in accordance with Ind AS and SEBI regulations.
Financial highlights
Consolidated revenue from operations for Q1 FY27 was ₹22,211 million, up from ₹18,789 million in Q1 FY26 and ₹22,722 million in Q4 FY26.
Consolidated profit for the period was ₹564 million, compared to ₹1,193 million in Q4 FY26 and ₹1,025 million in Q1 FY26.
Standalone revenue from operations for Q1 FY27 was ₹671 million, compared to ₹703 million in Q4 FY26 and ₹595 million in Q1 FY26.
Standalone profit for the period was ₹74 million, compared to ₹571 million in Q4 FY26 and ₹57 million in Q1 FY26.
Outlook and guidance
No explicit forward-looking guidance provided, but results were reviewed and approved by the Board, indicating ongoing operational focus.
Latest events from Jubilant Pharmova
- FY26 revenue up 14%, but net profit fell on exceptional costs; ₹5/share dividend proposed.530019
Q4 25/26 - Revenue up 17% YoY to ₹21,161 million; API business divested; net profit ₹558 million.530019Q3 25/26
- Radiopharma and Sterile Injectables drove double-digit revenue growth and margin expansion.530019Q2 25/26
- Q1 FY26 delivered ₹18,789 million revenue, margin gains, and API business sale reclassification.530019Q1 25/26
- Net profit surged on SOFIE sale, margin expansion, and operational gains.530019Q2 24/25
- Q1 profit surged on SOFIE sale, with strong revenue growth and reduced leverage.530019Q1 24/25
- Strong revenue and profit growth, margin expansion, and debt reduction supported by SOFIE sale.530019Q4 24/25
- Strong revenue, profit, and margin growth, with deleveraging and key regulatory progress.530019Q3 24/25